Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 115Terminated 22Recruiting 9Active not recruiting 8Withdrawn 5Unknown 5Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Leukemia, Myeloid, Acute 26Colorectal Neoplasms 26Neoplasms 24Neoplasm Metastasis 23Recurrence 22Multiple Myeloma 22Advanced Solid Tumors 19Lymphoma, B-Cell 18Breast Neoplasms 18Lung Neoplasms 14Pancreatic Neoplasms 13Glioblastoma 13Melanoma 12Hematologic Neoplasms 12Carcinoma, Hepatocellular 12Lymphoma 11Glioma 11Brain Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia 10Advanced Solid Tumor 10Prostatic Neoplasms 9Ovarian Neoplasms 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Esophageal Neoplasms 8

Interventions

cemiplimab 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Gliosarcoma × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡